SARS-CoV-2 Antibody Test
Viravaxx recently developed a simple and robust SARS-CoV-2 interaction assay mimicking SARS-CoV-2 binding to its receptor ACE2. The read-out of this ELISA based assay identifies antibodies with protective potential against SARS-CoV-2 and emerging SARS-CoV-2 variants.
The assay, also referred to as SARS-CoV-2 Neutralization Antibody Detection Test, or SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT), is protected by Viravaxx’ worlwide patent application. It detects antibodies against SARS-CoV-2 that block the interaction between RBD, the binding domain of the viral spike protein, with ACE2, the cell surface receptor. In cooperation with a national diagnostic center of excellence, the assay is set to become the gold standard as reference test for assessing the correlate of protection, protective immunity, and the efficacy of vaccine candidates crucial to control the COVID-19 pandemic.
The assay comes in a 96 well ELISA format with ACE2 linked to the plate and appropriately labeled RBD used for detection. Viravaxx currently cross-validates its proprietary assay in large clinical trial settings which investigate neutralizing antibody response in convalescent patients.